Thanks for pointing that out Asteria.
Price action I think is simply put down to what you already mentioned - Biotech has had a fall from grace globally.
Sentiment will change and I suspect we will see a rush of funds back into Biotech when the markets turn. Based on current trajectory, BOT will be quite heavily de-risked and very attractive.
I do feel for ex-holders, it's been a bad past but the SP acquisition has breathed new life into this company.
Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-53
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $689.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.5¢ | $1.784M | 4.691M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248028 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 356327 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |